Gregory Sullivan, MD
Tonix Pharmaceuticals · Tonix Pharmaceuticals, Inc. · Medical Monitor
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gregory Sullivan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06045793 · Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)Tonix Pharmaceuticals, Inc. · terminated · Cocaine Use, Cocaine Intoxication, Cocaine Toxicity · study director
- Ph2NCT05686408 · Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)Tonix Pharmaceuticals, Inc. · completed · Depression, Depressive Disorder, Depressive Symptoms · study director
- Ph2NCT05679908 · A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineTonix Pharmaceuticals, Inc. · completed · Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura · study director
- Ph2NCT05372887 · Safety and Efficacy Study of TNX-102 SL in Participants With PTSDTonix Pharmaceuticals, Inc. · withdrawn · PTSD · study director
- Ph3NCT05273749 · A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · completed · Fibromyalgia · study director
- Ph2NCT04996056 · An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) SubjectsTonix Pharmaceuticals, Inc. · withdrawn · Cocaine Intoxication · study director
- Ph3NCT04508621 · A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · completed · Fibromyalgia · study director
- Ph3NCT04172831 · A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With FibromyalgiaTonix Pharmaceuticals, Inc. · completed · Fibromyalgia · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Development of TNX-1300 (Double Mutant Cocaine Esterase) for the Treatment of Life-Threatening Cocaine IntoxicationU01DA056245 · NIDA · TONIX PHARMACEUTICALS, INC. · PI GREGORY M SULLIVAN · fiscal years 2022 to 2025Named on NCT06045793
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.